KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
48 hedge funds and large institutions have $278M invested in KalVista Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 3 closing their positions.
733% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 3
442% more capital invested
Capital invested by funds: $51.3M → $278M (+$227M)
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
85% more funds holding
Funds holding: 26 → 48 (+22)
14.63% more ownership
Funds ownership: 58.49% → 73.12% (+15%)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$14.3M |
| 2 |
VMI
VHCP Management II
New York
|
+$10.3M |
| 3 |
DM
Deerfield Management
New York
|
+$8.79M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$8.23M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$545K |
| 2 |
TI
Telemetry Investments
New York
|
-$529K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$232K |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
-$167K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$33.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$2K | -231 | Closed |
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$135 | +10 | New |
|
KALV Hedge Fund Activity: Q3 2018 in Review
48 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2018, worth a combined $278M — up 442% from $51.3M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KALV positions and 3 closed out — a net gain of 22 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Vivo Capital, adding an estimated $14.3M. The largest seller was Stanley-Laman Group, exiting entirely with an estimated $545K sold.
- 48 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2018, up from 26 in Q2 2018.
- Funds reported $278M of KalVista Pharmaceuticals stock for Q3 2018, up 442% quarter-over-quarter.
- 25 funds opened new KalVista Pharmaceuticals positions in Q3 2018 and 3 closed out, a net change of +22 holders.
- The largest KalVista Pharmaceuticals buyer in Q3 2018 was Vivo Capital, an estimated $14.3M added.
- The largest KalVista Pharmaceuticals seller in Q3 2018 was Stanley-Laman Group, an estimated $545K sold.
Based on aggregated 13F filings for Q3 2018.